MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 462561 | Name: OICR-0547
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

OICR-0547 is a closely related derivative of OICR-9429. OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction, while OICR-0547 is an inactive control compound that no longer binds to WDR5.

Chemical Structure

OICR-0547
OICR-0547
CAS#1801873-49-3

Theoretical Analysis

MedKoo Cat#: 462561

Name: OICR-0547

CAS#: 1801873-49-3

Chemical Formula: C28H29F3N4O4

Exact Mass: 542.2141

Molecular Weight: 542.56

Elemental Analysis: C, 61.99; H, 5.39; F, 10.50; N, 10.33; O, 11.80

Price and Availability

Size Price Availability Quantity
5mg USD 310.00 2 Weeks
10mg USD 520.00 2 Weeks
25mg USD 900.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
OICR-0547; OICR 0547; OICR0547
IUPAC/Chemical Name
N-(4-morpholino-3'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide
InChi Key
RFHOOFYUTGZPFH-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H29F3N4O4/c29-28(30,31)23-16-26(36)32-17-22(23)27(37)33-24-15-21(4-5-25(24)35-8-12-39-13-9-35)20-3-1-2-19(14-20)18-34-6-10-38-11-7-34/h1-5,14-17H,6-13,18H2,(H,32,36)(H,33,37)
SMILES Code
O=C(C1=CNC(C=C1C(F)(F)F)=O)NC2=CC(C3=CC(CN4CCOCC4)=CC=C3)=CC=C2N5CCOCC5
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction.
In vitro activity:
Optimization of this series using structure-guided medicinal chemistry resulted in OICR-9429 (1) (Fig. 4a), which binds to WDR5 with high affinity (KD = 93 ± 28 nM, Supplementary Fig. 11) and competitively disrupts its interaction with a high-affinity Wdr5-INteracting (WIN) peptide of MLL (Kdisp = 64 ± 4 nM, Fig. 4b). OICR-9429 is highly selective for WDR5, as it showed no significant binding to or inhibition of 22 human methyltransferases, 9 different WD40- and histone reader domains and a panel of over 250 human kinase, GPCR, ion channel, and transporter drug targets (Supplementary Table 3, 4). Reference: Nat Chem Biol. 2015 Aug;11(8):571-578. https://pubmed.ncbi.nlm.nih.gov/26167872/
In vivo activity:
This study confirmed that OICR-9429 injection inhibited the expression of H3K4me3. As previously described, Wdr5 inhibition led to fibroblast senescence. To validate these findings in vivo, this study treated mice with Ang II and with or without OICR-9429 injection. This study finally proved that the Wdr5 inhibitor OICR9429 significantly reduced Ang-II-induced cardiac fibrosis and increased the expression of P21 in cardiac fibroblasts. Reference: Biomolecules. 2022 Oct 27;12(11):1574. https://pubmed.ncbi.nlm.nih.gov/36358925/
Solvent mg/mL mM comments
Solubility
DMSO 100.0 184.31
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 542.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Getlik M, Smil D, Zepeda-Velázquez C, Bolshan Y, Poda G, Wu H, Dong A, Kuznetsova E, Marcellus R, Senisterra G, Dombrovski L, Hajian T, Kiyota T, Schapira M, Arrowsmith CH, Brown PJ, Vedadi M, Al-Awar R. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). J Med Chem. 2016 Mar 24;59(6):2478-96. doi: 10.1021/acs.jmedchem.5b01630. Epub 2016 Mar 9. PMID: 26958703. 2. Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KVM, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. Nat Chem Biol. 2015 Aug;11(8):571-578. doi: 10.1038/nchembio.1859. Epub 2015 Jul 13. Erratum in: Nat Chem Biol. 2015 Oct;11(10):815. PMID: 26167872; PMCID: PMC4511833. 3. Yuan J, Peng H, Mo B, Yin C, Fang G, Li Y, Wang Y, Chen R, Wang Q. Inhibition of Wdr5 Attenuates Ang-II-Induced Fibroblast-to-Myofibroblast Transition in Cardiac Fibrosis by Regulating Mdm2/P53/P21 Pathway. Biomolecules. 2022 Oct 27;12(11):1574. doi: 10.3390/biom12111574. PMID: 36358925; PMCID: PMC9687631. 4. Zhou Q, Chen X, He H, Peng S, Zhang Y, Zhang J, Cheng L, Liu S, Huang M, Xie R, Lin T, Huang J. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer. Theranostics. 2021 Mar 4;11(10):4809-4824. doi: 10.7150/thno.55814. PMID: 33754029; PMCID: PMC7978315.
In vitro protocol:
1. Getlik M, Smil D, Zepeda-Velázquez C, Bolshan Y, Poda G, Wu H, Dong A, Kuznetsova E, Marcellus R, Senisterra G, Dombrovski L, Hajian T, Kiyota T, Schapira M, Arrowsmith CH, Brown PJ, Vedadi M, Al-Awar R. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). J Med Chem. 2016 Mar 24;59(6):2478-96. doi: 10.1021/acs.jmedchem.5b01630. Epub 2016 Mar 9. PMID: 26958703. 2. Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KVM, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. Nat Chem Biol. 2015 Aug;11(8):571-578. doi: 10.1038/nchembio.1859. Epub 2015 Jul 13. Erratum in: Nat Chem Biol. 2015 Oct;11(10):815. PMID: 26167872; PMCID: PMC4511833.
In vivo protocol:
1. Yuan J, Peng H, Mo B, Yin C, Fang G, Li Y, Wang Y, Chen R, Wang Q. Inhibition of Wdr5 Attenuates Ang-II-Induced Fibroblast-to-Myofibroblast Transition in Cardiac Fibrosis by Regulating Mdm2/P53/P21 Pathway. Biomolecules. 2022 Oct 27;12(11):1574. doi: 10.3390/biom12111574. PMID: 36358925; PMCID: PMC9687631. 2. Zhou Q, Chen X, He H, Peng S, Zhang Y, Zhang J, Cheng L, Liu S, Huang M, Xie R, Lin T, Huang J. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer. Theranostics. 2021 Mar 4;11(10):4809-4824. doi: 10.7150/thno.55814. PMID: 33754029; PMCID: PMC7978315.
1: Grebien F, Vedadi M, Getlik M, et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia [published correction appears in Nat Chem Biol. 2015 Oct;11(10):815]. Nat Chem Biol. 2015;11(8):571-578. doi:10.1038/nchembio.1859 2: Getlik, M., Smil, D., Zepeda-Velazquez, C., Bolshan, Y., Poda, G., Wu, H., ... & Al-Awar, R. (2016). Structure-based optimization of a small molecule antagonist of the interaction between WD repeat-containing protein 5 (WDR5) and mixed-lineage leukemia 1 (MLL1). Journal of medicinal chemistry, 59(6), 2478-2496. 3: Wolf, E., Herasymenko, O., Kutera, M., Lento, C., Arrowsmith, C., Ackloo, S., & Wilson, D. (2024). Quantitative Hydrogen–Deuterium Exchange Mass Spectrometry for Simultaneous Structural Characterization and Affinity Indexing of Single Target Drug Candidate Libraries. Analytical Chemistry.